Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Comin Anduix, Begoña ^a   Lee, Yohan ^b   Jalil, Jason ^a   Algazi, Alain ^a   de la Rocha, Pilar ^a   Camacho, Luis H ^c   Bozon, Viviana A ^d   Bulanhagui, Cecile A ^d   Seja, Elisabeth ^a   Villanueva, Arturo ^a   Straatsma, Bradley R ^e   Gualberto, Antonio ^d   Economou, James S ^a,b   Glaspy, John A ^a,b   Gomez Navarro, Jesus ^d   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Oncology Consultants   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CISPLATIN; CORTICOSTEROID; DACARBAZINE; GEFITINIB; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HLA A ANTIGEN; HLA DR ANTIGEN; ILX 651; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; MELAN A; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; TEMOZOLOMIDE; TETRAMER; THALIDOMIDE; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG; VINBLASTINE; CP-675,206; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOLOGICAL MONITORING; IRIDOCYCLITIS; LEUKOCYTOCLASTIC VASCULITIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; PLASMAPHERESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; ROSACEA; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TOXIC HEPATITIS; TRANSIENT ACANTHOLYTIC DERMATOSIS; TUMOR IMMUNITY; TUMOR REGRESSION; BIOSYNTHESIS; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; MIDDLE AGED; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CLUSTER ANALYSIS; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNE SYSTEM; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES;

EID: 44949119433     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-22     Document Type: Article

References (49)

1. Brunet JF Denizot F Luciani MF Roux-Dosseto M Suzan M Mattei MG Golstein P A new member of the immunoglobulin superfamily - CTLA-4 Nature 1987, 328:267-270. 10.1038/328267a0 3496540
2. Walunas TL Lenschow DJ Bakker CY Linsley PS Freeman GJ Green JM Thompson CB Bluestone JA CTLA-4 can function as a negative regulator of T cell activation Immunity 1994, 1:405-413. 10.1016/1074-7613(94)90071-X 7882171
3. Chambers CA Kuhns MS Egen JG Allison JP CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 2001, 19:565-594. 10.1146/ annurev.immunol.19.1.565 11244047
4. Wang XB Giscombe R Yan Z Heiden T Xu D Lefvert AK Expression of CTLA-4 by human monocytes Scand J Immunol 2002, 55:53-60. 10.1046/ j.0300-9475.2001.01019.x 11841692
5. Teft WA Kirchhof MG Madrenas J A molecular perspective of CTLA-4 function Annu Rev Immunol 2006, 24:65-97. 10.1146/ annurev.immunol.24.021605.090535 16551244
6. Lee KM Chuang E Griffin M Khattri R Hong DK Zhang W Straus D Samelson LE Thompson CB Bluestone JA Molecular basis of T cell inactivation by CTLA-4 Science 1998, 282:2263-2266. 10.1126/science.282.5397.2263 9856951
7. Hodi FS Mihm MC Soiffer RJ Haluska FG Butler M Seiden MV Davis T Henry-Spires R MacRae S Willman A Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci USA 2003, 100:4712-4717. 153621 12682289 10.1073/pnas.0830997100
8. Phan GQ Yang JC Sherry RM Hwu P Topalian SL Schwartzentruber DJ Restifo NP Haworth LR Seipp CA Freezer LJ Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 2003, 100:8372-8377. 166236 12826605 10.1073/pnas.1533209100
9. Attia P Phan GQ Maker AV Robinson MR Quezado MM Yang JC Sherry RM Topalian SL Kammula US Royal RE Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 2005, 23:6043-6053. 1473965 16087944 10.1200/JCO.2005.06.205
10. Maker AV Phan GQ Attia P Yang JC Sherry RM Topalian SL Kammula US Royal RE Haworth LR Levy C Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study Ann Surg Oncol 2005, 12:1005-1016. 1473970 16283570 10.1245/ASO.2005.03.536
11. Sanderson K Scotland R Lee P Liu D Groshen S Snively J Sian S Nichol G Davis T Keler T Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma J Clin Oncol 2005, 23:741-750. 10.1200/ JCO.2005.01.128 15613700
12. Ribas A Camacho LH Lopez-Berestein G Pavlov D Bulanhagui CA Millham R Comin-Anduix B Reuben JM Seja E Parker CA Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol 2005, 23:8968-8977. 10.1200/JCO.2005.01.109 16204013
13. Maker AV Yang JC Sherry RM Topalian SL Kammula US Royal RE Hughes M Yellin MJ Haworth LR Levy C Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother 2006, 29:455-463. 2134804 16799341 10.1097/01.cji.0000208259.73167.58
14. Reuben JM Lee BN Li C Gomez-Navarro J Bozon VA Parker CA Hernandez IM Gutierrez C Lopez-Berestein G Camacho LH Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma Cancer 2006, 106:2437-2444. 10.1002/cncr.21854 16615096
15. Downey SG Klapper JA Smith FO Yang JC Sherry RM Royal RE Kammula US Hughes MS Allen TE Levy CL Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 2007, 13:6681-6688. 2147083 17982122 10.1158/1078-0432.CCR-07-0187
16. Korman AJ Peggs KS Allison JP Checkpoint blockade in cancer immunotherapy Adv Immunol 2006, 90:297-339. 1951510 16730267
17. Peggs KS Quezada SA Korman AJ Allison JP Principles and use of anti-CTLA4 antibody in human cancer immunotherapy Curr Opin Immunol 2006, 18:206-213. 10.1016/j.coi.2006.01.011 16464564
18. Leach DR Krummel MF Allison JP Enhancement of antitumor immunity by CTLA-4 blockade Science 1996, 271:1734-1736. 10.1126/ science.271.5256.1734 8596936
19. O'Mahony D Morris JC Quinn C Gao W Wilson WH Gause B Pittaluga S Neelapu S Brown M Fleisher TA A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res 2007, 13:958-964. 10.1158/1078-0432.CCR-06-1974 17289891
20. Shevach EM CD4+ CD25+ suppressor T cells: More questions than answers Nat Rev Immunol 2002, 2:389-400. 12093005
21. Grohmann U Orabona C Fallarino F Vacca C Calcinaro F Falorni A Candeloro P Belladonna ML Bianchi R Fioretti MC Puccetti P CTLA-4-Ig regulates tryptophan catabolism in vivo Nat Immunol 2002, 3:1097-1101. 10.1038/ ni846 12368911
22. Fallarino F Grohmann U Hwang KW Orabona C Vacca C Bianchi R Belladonna ML Fioretti MC Alegre ML Puccetti P Modulation of tryptophan catabolism by regulatory T cells Nat Immunol 2003, 4:1206-1212. 10.1038/ni1003 14578884
23. Munn DH Sharma MD Hou D Baban B Lee JR Antonia SJ Messina JL Chandler P Koni PA Mellor AL Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 2004, 114:280-290. 449750 15254595
24. Paust S Lu L McCarty N Cantor H Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease Proc Natl Acad Sci USA 2004, 101:10398-10403. 478583 15235129 10.1073/pnas.0403342101
25. Jinushi M Hodi FS Dranoff G Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity Proc Natl Acad Sci USA 2006, 103:9190-9195. 1482588 16754847 10.1073/pnas.0603503103
26. Schneider H Downey J Smith A Zinselmeyer BH Rush C Brewer JM Wei B Hogg N Garside P Rudd CE Reversal of the TCR stop signal by CTLA-4 Science 2006, 313:1972-1975. 10.1126/science.1131078 16931720
27. Contardi E Palmisano GL Tazzari PL Martelli AM Fala F Fabbi M Kato T Lucarelli E Donati D Polito L CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction Int J Cancer 2005, 117:538-550. 10.1002/ijc.21155 15912538
28. Keilholz U Weber J Finke JH Gabrilovich DI Kast WM Disis ML Kirkwood JM Scheibenbogen C Schlom J Maino VC Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy J Immunother 2002, 25:97-138. 10.1097/ 00002371-200203000-00001 12074049
29. Comin-Anduix B Gualberto A Glaspy JA Seja E Ontiveros M Reardon DL Renteria R Englahner B Economou JS Gomez-Navarro J Ribas A Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays Clin Cancer Res 2006, 12:107-116. 10.1158/1078-0432.CCR-05-0136 16397031
30. Marincola FM In support of descriptive studies; relevance to translational research J Transl Med 2007, 5:21. 1871566 17474987 10.1186/ 1479-5876-5-21
31. Ribas A Bozon VA Lopez-Berestein G Pavlov D Reuben JM Parker CA Seja E Glaspy JA Gomez-Navarro J Camacho LH Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma J Clin Oncol 2005, 23(suppl):716s. Abstract 7524
32. Gordon LK Ribas A Nusinowitz S Butterfield LH Glaspy JA Economou JS Straatsma BR Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma Control Clin Trials 2004, 25:400-407. 10.1016/j.cct.2004.06.002 15296814
33. Straatsma BR Nusinowitz S Young TA Gordon LK Chun MW Rosen C Seja E Economou JS Glaspy JA Bozon V Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma Am J Ophthalmol; 2007.
34. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205 10655437
35. Maecker HT Moon J Bhatia S Ghanekar SA Maino VC Payne JK Kuus-Reichel K Chang JC Summers A Clay TM Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT BMC Immunol 2005, 6:17. 1190174 16026627 10.1186/1471-2172-6-17
36. Butterfield LH Meng WS Koh A Vollmer CM Ribas A Dissette VB Faull K Glaspy JA McBride WH Economou JS T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein J Immunol 2001, 166:5300-5308. 11290817
37. Perfetto SP Chattopadhyay PK Roederer M Seventeen-colour flow cytometry: unravelling the immune system Nat Rev Immunol 2004, 4:648-655. 10.1038/ nri1416 15286731
38. Muthukumar T Dadhania D Ding R Snopkowski C Naqvi R Lee JB Hartono C Li B Sharma VK Seshan SV et al Messenger RNA for FOXP3 in the urine of renal-allograft recipients N Engl J Med 2005, 353:2342-2351. 10.1056/ NEJMoa051907 16319383
39. Baratelli F Lin Y Zhu L Yang SC Heuze-Vourc'h N Zeng G Reckamp K Dohadwala M Sharma S Dubinett SM Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells J Immunol 2005, 175:1483-1490. 16034085
40. Maker AV Attia P Rosenberg SA Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade J Immunol 2005, 175:7746-7754. 1473972 16301685
41. Eisen MB Spellman PT Brown PO Botstein D Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci USA 1998, 95:14863-14868. 24541 9843981 10.1073/pnas.95.25.14863
42. Comin-Anduix B Lee Y Jalil J de la Rocha P Seja E Bozon VA Camacho LH Economou JS Glaspy JA Gomez-Navarro J Ribas A Immunological assays to differentiate responders from nonresponders after CTLA blockade with CP-675,206 [abstract] Proc Int Soc Biol Ther Cancer; 2006.
43. Blansfield JA Beck KE Tran K Yang JC Hughes MS Kammula US Royal RE Topalian SL Haworth LR Levy C Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 2005, 28:593-598. 2154350 16224277 10.1097/01.cji.0000178913.41256.06
44. Rosenberg SA Progress in human tumour immunology and immunotherapy Nature 2001, 411:380-384. 10.1038/35077246 11357146
45. Liu H Hu B Xu D Liew FY CD4+CD25+ regulatory T cells cure murine colitis: The role of IL-10, TGF-beta, and CTLA4 J Immunol 2003, 171:5012-5017. 14607897
46. Read S Greenwald R Izcue A Robinson N Mandelbrot D Francisco L Sharpe AH Powrie F Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo J Immunol 2006, 177:4376-4383. 16982872
47. Bruggemann M Williams GT Bindon CI Clark MR Walker MR Jefferis R Waldmann H Neuberger MS Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies J Exp Med 1987, 166:1351-1361. 2189658 3500259 10.1084/jem.166.5.1351
48. Hori S Nomura T Sakaguchi S Control of regulatory T cell development by the transcription factor Foxp3 Science 2003, 299:1057-1061. 10.1126/ science.1079490 12522256
49. Fontenot JD Rasmussen JP Williams LM Dooley JL Farr AG Rudensky AY Regulatory T cell lineage specification by the forkhead transcription factor foxp3 Immunity 2005, 22:329-341. 10.1016/j.immuni.2005.01.016 15780990